NDA 021201 · Chemisch Fbrk Krsslr
Asclera
Polidocanol · Intravenous · Sclerosing Agent
NovelLast checked: Nov 19, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Mar 30, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
42
7 Phase 3, 4 recruiting
FAERS reports
450
263 serious, 15 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 16, 2025.
Asclera ® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. Asclera (polidocanol) is a sclerosing agent indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3mm in diameter. ( 1 )
Mechanism: The active ingredient of Asclera is polidocanol. Polidocanol is a sclerosing agent that locally damages the endothelium of blood vessels. When injected intravenously, polidocanol induces endothelial damage. Platelets then aggregate at the site of damage and attach to the venous wall. Eventually, a dense network of platelets, cellular debris, and fibrin occludes the vessel. Finally, the occluded vein is replaced with connective fibrous tissue.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 30, 2010 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
2 products under this application
- ASCLERA · POLIDOCANOL 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- ASCLERA · POLIDOCANOL 20MG/2ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Polidocanol" as an intervention, any sponsor and status, largest first.
- A Multicenter Prospective Clinical Study of Endoscopic Foam Sclerotherapy for Internal HemorrhoidsPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT04398823 · 700 participants (planned) · Start May 15, 2020 · Primary completion Dec 31, 2020
Drug: Sclerosing foam of Lauromacrogol; Sclersing liqiud of Lauromacrogol · For: Grade/Stage I Hemorrhoids; Prolapsed Grade II Internal Haemorrhoid; Prolapsed Grade III Internal Haemorrhoid
Sites: Shanghai, China
- Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) IncompetencePivotal-lookingCompleted
Boston Scientific CorporationIndustry
NCT01072877 · 279 participants · Start Dec 2010 · Primary completion Dec 2011
Drug: Polidocanol injectable foam (PEM); Placebo Vehicle · For: Varicose Veins
Sites: Laguna Hills, California; San Diego, California; Washington D.C., District of Columbia · 20 sites in all
- Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) IncompetencePivotal-lookingCompleted
Boston Scientific CorporationIndustry
NCT01231373 · 235 participants · Start Nov 2010 · Primary completion Sep 2011
Drug: polidocanol injectable foam, 0.125%; polidocanol injectable foam, 0.5% and 2 more · For: Varicose Veins
Sites: Dothan, Alabama; San Diego, California; Lafayette, Indiana · 12 sites in all
- Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal DiseaseCompleted
Societa Italiana di Chirurgia ColoRettaleResearch network
NCT03791775 · 183 participants · Start Jan 2, 2019 · Primary completion Jun 2, 2019
Drug: Polidocanol foam (Atossisclerol® 3%) · For: Second-degree Hemorrhoids
Sites: Catanzaro, Italy
- RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV InsufficiencyPivotal-lookingCompleted
Societe Francaise de PhlebologieAcademic, hospital or other
NCT05468450 · 161 participants · Start Jul 1, 2015 · Primary completion Aug 31, 2016
Drug: Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant · For: Varicose Veins of Lower Limb
- ESGVS: Sclerotherapy With LauromacrogolPivotal-lookingCompleted
University Hospital, GrenobleAcademic, hospital or other
NCT00348764 · 150 participants · Start Mar 2004
Drug: lauromacrogol · For: Venous Insufficiency; Saphenous Vein
Sites: Grenoble, France
- Polidocanol Foam Versus Rubber Band Ligation in the Treatment of Hemorrhoidal DiseasePivotal-lookingCompleted
Universidade do PortoAcademic, hospital or other
NCT04091763 · 120 participants · Start Aug 1, 2018 · Primary completion Jul 1, 2020
Drug: Polidocanol Injectable Foam · For: Hemorrhoids, Internal
Sites: Porto, Portugal
- Investigation Into the Pathophysiology and Treatment of Varicose VeinsPivotal-lookingCompleted
University of SurreyAcademic, hospital or other
NCT06192472 · 120 participants · Start Apr 2013 · Primary completion Jul 2015
Drug: 1% Sodium Tetradecyl Sulphate; 3% Sodium Tetradecyl Sulphate and 2 more · For: Varicose Veins
Sites: Guildford, United Kingdom · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- deep vein thrombosis35
- pain28
- pruritus28
- off label use27
- erythema26
- dizziness24
- swelling24
- injection site pain23
- pain in extremity23
- nausea22
- urticaria22
- drug ineffective20
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 21 |
| 2014 | 6 |
| 2015 | 19 |
| 2016 | 34 |
| 2017 | 48 |
| 2018 | 64 |
| 2019 | 28 |
| 2020 | 43 |
| 2021 | 27 |
| 2022 | 46 |
| 2023 | 19 |
| 2024 | 18 |
| 2025 | 24 |
| 2026 | 39 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.
Bossart S, Daneluzzi C, Cazzaniga S, et al. · J Eur Acad Dermatol Venereol 2023 · Systematic Review
- The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex Scanning and Treatment of Superficial Truncal Reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology.
Gloviczki P, Lawrence PF, Wasan SM, et al. · J Vasc Surg Venous Lymphat Disord 2023 · Meta-Analysis, Practice Guideline
- Polidocanol Sclerotherapy in Pyogenic Granulomas.
Khurana A, Mathachan SR · Dermatol Surg 2022 · Clinical Trial
- Treating telangiectasias: my method.
Ferrara F, Ferrara G · Minerva Cardioangiol 2013 · Clinical Trial
- Injection sclerotherapy for varicose veins.
Tisi PV, Beverley C, Rees A · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Injection sclerotherapy for varicose veins.
de Ávila Oliveira R, Riera R, Vasconcelos V, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Chemisch Fbrk Krsslr
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.